Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib plus salvage chemotherapy in relapsed/refractory FLT3-mutated AML
CTR20200493Phase 3Active
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of crenolanib in acute myeloid leukemia (AML), sponsored by AROG Pharmaceuticals, Inc.. Started Apr 2020; status: active.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20200493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200493.